Molecular features of the hepatitis B virus nucleocapsid T-cell epitope 18-27: Interaction with HLA and T-cell receptor

Hepatology

Volumn 26, Issue 4, 1997, Pages 1027-1034

  Bertoletti, Antonio ^a   Southwood, Scott ^b   Chesnut, Robert ^b   Sette, Alessandro ^b   Falco, Michela ^c   Ferrara, Giovan Battista ^c   Penna, Amalia ^a   Boni, Carolina ^a   Fiaccadori, Franco ^a   Ferrari, Carlo ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b CYTEL CORPORATION   (United States)

^c CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A ANTIGEN; HLA ANTIGEN; HLA ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR;

ADULT; ANTIGEN BINDING; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGENICITY; ARTICLE; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; FEMALE; HEPATITIS B; HLA SYSTEM; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; VIRUS NUCLEOCAPSID;

EID: 12644276399     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510260435     Document Type: Article

References (40)

1. Beasley RP, Lin C-C, Hwang LY, Chen C-S. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. Lancet 1981;2:1129-1133.
2. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
3. Perrillo RP. Antiviral therapy of chronic hepatitis B: past, present and future. J Hepatol 1993;17(S3):56-63.
4. Guidotti LG, Ishikava T, Hobbs MV, Matzke B, Schreiber RD, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996;4:25-36.
5. Ferrari C, Bertoletti A, Penna A, Cavalli A, Valli A, Missale G, Pilli M, et al. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest 1991;88:214-222.
6. Nayersina R, Fowler P, Guilhot S, Missale G, Cerny A, Schlicht HJ, Vitiello A, et al. HLA-A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 1993;150:4659-4671.
7. Penna A, Chisari FV, Bertoletti A, Missale G, Fowler P, Giuberti T, Fiaccadori F, et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991;174:1565-1570.
8. Rehermann B, Chisari FV. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995;181:1047-1058.
9. Ferrari C, Penna A, Bertoletti A, Valli A, Degli Antoni A, Giuberti T, Cavalli A, et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990;145:3442-3449.
10. + T cell population during sero-conversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol 1995;69:3358-3368.
11. Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, Yuan L, et al. Development of a lipopeptide-based vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995;1:341-349.
12. Bertoletti A, Chisari FV, Penna A, Guilhot S, Galati L, Missale G, Fowler P, et al. Definition of an optimal cytotoxic T cell epitope within the hepatitis B virus nucleocapsid protein. J Virol 1993;67:2376-2380.
13. Del Guercio MF, Sidney J, Hermanson G, Perez C, Grey HM, Kubo RT, Sette A. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J Immunol 1995;154:685-693.
14. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993;74:929-937.
15. Madden DR, Garboczi DN, Wiley DC. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 1993;75:693-706.
16. Bertoletti A, Costanzo A, Chisari FV, Levrero M, Artini M, Sette A, Penna A, et al. Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med 1994;180:933-943.
17. Bertoletti A, Sette A, Chisari FV, Penna A, Levrero M, De Carli M, Fiaccadori F, et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonist for antiviral cytotoxic T cells. Nature 1994;369: 407-410.
18. Fernandez-Vina MA, Falco M, Sun Y, Stastny P. DNA typing for class I alleles: I. Subsets of HLA-A2 and of -A28. Hum Immunol 1992;33: 163-173.
19. Barouch D, Friede T, Stevanovic S, Tussey L, Smith K, Rowland-Jones S, Braud V, et al. HLA-A2 subtypes are functionally distinct in peptide binding and presentation. J Exp Med 1995;182:1847-1856.
20. Rotzschke O, Falk K, Stevanovic S, Jung G, Rammense HG. Peptide motifs of closely related HLA class I molecules encompass substantial differences. Eur J Immunol 1992;22:2453-2456.
21. Teng JMC, Hogan KT. Both major and minor peptide-binding pockets in HLA-A2 influence the presentation of influenza virus matrix peptide to cytotoxic T lymphocytes. Mol Immunol 1994;31:459-470.
22. Tussey LG, Matsui M, Rowland-Jones S, Warburton R, Frelinger JA, McMichael A. Analysis of mutant HLA-A2 molecules. Differential effects on peptide binding and CTL recognition. J Immunol 1994;152:1213-1221.
23. Hogan KT, Clayberger C, Le AT, Walk SF, Ridge JP, Parham P, Krensky AM, et al. Cytotoxic T lymphocyte-defined epitope differences between HLA-A2.1 and HLA-A2.2 map to two distinct regions of the molecule. J Immunol 1988;141:4005-4011.
24. Matsui M, Moots RJ, McMichael AJ, Frelinger JA. Significance of the six peptide-binding pockets of HLA-A2.1 in influenza A matrix peptide-specific cytotoxic T-lymphocyte reactivity. Hum Immunol 1994;41:160-166.
25. McMichael A, Gotch FM, Santos-Aguado J, Strominger J. Effect of mutations and variations of HLA-A2 on recognition of a virus peptide epitope by cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 1988;85:9194-9198.
26. Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M, Chisari FV, et al. Long lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996;98:1185-1194.
27. Doherty PC, Allan W, Eichelberger M, Carding SR. Role of ab and gd T cell subsets in viral immunity. Annu Rev Immunol 1992;10:123-151.
28. Gotch F, Rothbard J, Howland K, Townsend A, McMichael A. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature 1987;326:881-882.
29. Fremont DH, Matsumura M, Stura EA, Peterson PA, Wilson IA. Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb. Science 1992;257:919-927.
30. Levitsky V, Zhang Q-J, Levitskaya J, Masucci MG. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4. J Exp Med 1996;183:915-926.
31. Ferrari C, Bertoletti A, Fiaccadori F, Chisari FV. Is antigenic variability a strategy adopted by hepatitis B virus to escape cytotoxic T-lymphocyte surveillance? Semin Virol 1996;7:23-30.
32. Kersh GJ, Allen PM. Essential flexibility in the T-cell recognition of antigen. Nature 1996;380:495-498.
33. Sloan-Lancaster J, Evavold BD, Allen PM. Induction of T cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 1993;363:156-159.
34. Jameson SC, Carbone FR, Bevan MJ. Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells. J Exp Med 1993;177:1541-1550.
35. Krausa P, Brywka M III, Savage D, Hui KM, Bunce M, Ngai JLF, Teo DLT, et al. Genetic polymorphism within HLA-A02: significance of allelic variants within different populations. Tissue Antigens 1995;45: 223-231.
36. Sudo T, Kamikawaji N, Kimura A, Date Y, Savoie CJ, Nakashima H, Furuichi E, et al. Differences in MHC class I self peptide repertoires among HLA-A2 subtypes. J Immunol 1995;155:4749-4756.
37. Rivoltini L, Loftus DJ, Barracchini K, Arienti F, Mazzocchi A, Biddison WE, Salgaller ML, et al. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. J Immunol 1996;156:3882-3891.
38. Brooks JM, Murray RJ, Thomas WA, Kurilla MG, Rickinson AB. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. J Exp Med 1993;178:879-887.
39. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994; 76:241-251.
40. von Herrath MG, Yokoyama M, Dockter J, Oldstone MBA, Whitton JL. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol 1995;70:1072-1079.